Waldenstrom’s Macroglobulinemia
Show Only Open Trials
1.
Phase I trial of anti-CD74 (hLL1) Antibody Therapy in B-cell malignancies
- Study Status: Closed to Enrollment
- Sponsor: Weill Cornell Medical College; Immunomedics, Inc.
2.
A Phase 1 Sequential Dose Escalation Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics, and Clinical Activity of CAL-101 in Patients with Select, Relapsed or Refractory Hematologic Malignancies
- Study Status: Open to Enrollment
- Sponsor: Calistoga Pharmaceuticals
- Disease Status and/or Stage: Relapsed or Refractory Hematological Malignancies
